UA65587C2 - Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus - Google Patents

Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus Download PDF

Info

Publication number: UA65587C2
Authority: UA; Ukraine
Prior art keywords: patient; differs; administered; tacrolimus; pharmaceutical composition
Prior art date: 1997-10-09

Application number

UA2000041980A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Baker Norton Pharma

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-09

Filing date

1998-09-10

Publication date

2004-04-15

1998-09-10 Application filed by Baker Norton Pharma, Us Health filed Critical Baker Norton Pharma

2004-04-15 Publication of UA65587C2 publication Critical patent/UA65587C2/uk

Links

229930182912 cyclosporin Natural products 0.000 title claims abstract description 65
238000000034 method Methods 0.000 title claims abstract description 60
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title claims abstract description 27
229960001967 tacrolimus Drugs 0.000 title claims abstract description 27
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title claims abstract description 27
231100000417 nephrotoxicity Toxicity 0.000 title claims abstract description 18
206010029155 Nephropathy toxic Diseases 0.000 title claims abstract description 17
230000007694 nephrotoxicity Effects 0.000 title claims abstract description 17
108010036941 Cyclosporins Proteins 0.000 title claims description 12
108010036949 Cyclosporine Proteins 0.000 claims abstract description 62
229960001265 ciclosporin Drugs 0.000 claims abstract description 62
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 61
150000003839 salts Chemical class 0.000 claims abstract description 29
229940043138 pentosan polysulfate Drugs 0.000 claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 15
238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
230000037396 body weight Effects 0.000 claims abstract description 7
238000002650 immunosuppressive therapy Methods 0.000 claims abstract description 4
239000002552 dosage form Substances 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 19
230000003902 lesion Effects 0.000 claims description 8
239000003826 tablet Substances 0.000 claims description 7
210000000987 immune system Anatomy 0.000 claims description 6
208000017169 kidney disease Diseases 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 5
239000000945 filler Substances 0.000 claims description 5
159000000000 sodium salts Chemical group 0.000 claims description 5
239000011230 binding agent Substances 0.000 claims description 4
239000007894 caplet Substances 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
230000003176 fibrotic effect Effects 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000007937 lozenge Substances 0.000 claims description 3
230000037390 scarring Effects 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
239000007903 gelatin capsule Substances 0.000 claims description 2
235000019359 magnesium stearate Nutrition 0.000 claims description 2
239000008108 microcrystalline cellulose Substances 0.000 claims description 2
229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
235000015424 sodium Nutrition 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000007939 sustained release tablet Substances 0.000 claims 2
230000006028 immune-suppresssive effect Effects 0.000 claims 1
231100000268 induced nephrotoxicity Toxicity 0.000 abstract description 6
238000011260 co-administration Methods 0.000 abstract description 4
230000008085 renal dysfunction Effects 0.000 abstract description 2
210000003734 kidney Anatomy 0.000 description 25
241000700159 Rattus Species 0.000 description 21
241001465754 Metazoa Species 0.000 description 9
206010016654 Fibrosis Diseases 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000004761 fibrosis Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000011282 treatment Methods 0.000 description 8
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
235000014659 low sodium diet Nutrition 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
230000003562 morphometric effect Effects 0.000 description 5
238000013425 morphometry Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000002265 prevention Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229940127291 Calcium channel antagonist Drugs 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
210000002565 arteriole Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001434 glomerular Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
101000653542 Homo sapiens Transcription factor-like 5 protein Proteins 0.000 description 2
241000721454 Pemphigus Species 0.000 description 2
102100030647 Transcription factor-like 5 protein Human genes 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000006378 damage Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
-1 for example Chemical class 0.000 description 2
206010061989 glomerulosclerosis Diseases 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
230000000495 immunoinflammatory effect Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
210000005239 tubule Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
240000000731 Fagus sylvatica Species 0.000 description 1
235000010099 Fagus sylvatica Nutrition 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
241001150538 Iria Species 0.000 description 1
206010023421 Kidney fibrosis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
238000013265 extended release Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
229940025770 heparinoids Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
208000013435 necrotic lesion Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000003214 pyranose derivatives Chemical group 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001180 sulfating effect Effects 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Cephalosporin Compounds (AREA)

UA2000041980A 1997-10-09 1998-09-10 Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus UA65587C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6294797P	1997-10-09	1997-10-09
PCT/US1998/021313 WO1999018961A1 (en)	1997-10-09	1998-10-09	Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus

Publications (1)

Publication Number	Publication Date
UA65587C2 true UA65587C2 (en)	2004-04-15

Family

ID=22045901

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000041980A UA65587C2 (en)	1997-10-09	1998-09-10	Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus

Country Status (23)

Country	Link
US (1)	US6187745B1 (pl)
EP (1)	EP1027053B1 (pl)
JP (1)	JP2001519392A (pl)
KR (1)	KR100515196B1 (pl)
CN (1)	CN1154492C (pl)
AT (1)	ATE269098T1 (pl)
AU (1)	AU748495B2 (pl)
BR (1)	BR9813860A (pl)
CA (1)	CA2304374A1 (pl)
CZ (1)	CZ297440B6 (pl)
DE (1)	DE69824619T2 (pl)
DK (1)	DK1027053T3 (pl)
ES (1)	ES2221714T3 (pl)
HU (1)	HUP0003904A3 (pl)
IL (1)	IL135235A0 (pl)
NO (1)	NO20001828L (pl)
NZ (1)	NZ503493A (pl)
PL (1)	PL191993B1 (pl)
PT (1)	PT1027053E (pl)
RU (1)	RU2191020C2 (pl)
SK (1)	SK285332B6 (pl)
UA (1)	UA65587C2 (pl)
WO (1)	WO1999018961A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001052867A1 (en)	2000-01-19	2001-07-26	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) *	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
IL160761A0 (en) *	2001-10-19	2004-08-31	Isotechnika Inc	Novel cyclosporin analog microemulsion preconcentrates
IL164185A0 (en) *	2002-04-16	2005-12-18	Fujisawa Pharmaceutical Co	Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
ES2399277T3 (es)	2004-05-27	2013-03-27	Baxter International Inc.	Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2010020423A2 (en)	2008-08-22	2010-02-25	Baxter Healthcare S.A.	Methods for treating bleeding disorders
JP6393453B2 (ja)	2010-01-14	2018-09-19	バクスアルタゲーエムベーハー	出血性障害を治療するための方法及び組成物
US8871741B2 (en) *	2010-01-15	2014-10-28	Icahn School Of Medicine At Mount Sinai	Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) *	2010-09-01	2012-01-25	吴洪	戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
EP2734213B1 (en)	2011-07-19	2018-06-06	Baxalta GmbH	Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
WO2013052380A2 (en)	2011-10-05	2013-04-11	Allergan, Inc.	Compositions for enhancing nail health
EP2885642B1 (en)	2012-08-14	2019-05-15	Baxalta GmbH	Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
KR101760510B1 (ko)	2014-12-18	2017-07-21	가톨릭대학교 산학협력단	메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) *	2014-12-18	2016-06-23	가톨릭대학교 산학협력단	메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016199161A2 (en) *	2015-06-12	2016-12-15	Swati Vishal Jajodia	A composition comprising pentosan polysulfate sodium for use in treatment of bladder outlet obstruction and/or lower urinary tract symptoms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3843241A1 (de) *	1988-12-22	1990-06-28	Skrezek Christian	Nephroprotektive infusionsloesung
EP0466315A3 (en)	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en)	1990-06-11	1993-04-20	Du Pont Merck Pharmaceutical Company	Treatment of organ transplantation rejection
GB9116836D0 (en) *	1991-08-05	1991-09-18	Sandoz Ltd	Organic compounds
US5605938A (en) *	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) *	1992-04-14	1995-01-27	Северо-Кавказский горно-металлургический институт	Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) *	1995-01-20	1997-11-04	Sigma Tau Ind Farmaceuti	Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) *	1995-02-03	1996-08-13	L T T Kenkyusho:Kk	腎不全治療剤
US5643892A (en) *	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases

1998
- 1998-09-10 UA UA2000041980A patent/UA65587C2/uk unknown
- 1998-10-01 US US09/168,974 patent/US6187745B1/en not_active Expired - Fee Related
- 1998-10-09 AT AT98952186T patent/ATE269098T1/de not_active IP Right Cessation
- 1998-10-09 EP EP98952186A patent/EP1027053B1/en not_active Expired - Lifetime
- 1998-10-09 AU AU97943/98A patent/AU748495B2/en not_active Ceased
- 1998-10-09 PL PL339774A patent/PL191993B1/pl not_active IP Right Cessation
- 1998-10-09 RU RU2000111495/14A patent/RU2191020C2/ru not_active IP Right Cessation
- 1998-10-09 NZ NZ503493A patent/NZ503493A/en unknown
- 1998-10-09 ES ES98952186T patent/ES2221714T3/es not_active Expired - Lifetime
- 1998-10-09 JP JP2000515596A patent/JP2001519392A/ja active Pending
- 1998-10-09 DE DE69824619T patent/DE69824619T2/de not_active Expired - Fee Related
- 1998-10-09 WO PCT/US1998/021313 patent/WO1999018961A1/en not_active Ceased
- 1998-10-09 CZ CZ20001274A patent/CZ297440B6/cs not_active IP Right Cessation
- 1998-10-09 HU HU0003904A patent/HUP0003904A3/hu unknown
- 1998-10-09 SK SK467-2000A patent/SK285332B6/sk unknown
- 1998-10-09 DK DK98952186T patent/DK1027053T3/da active
- 1998-10-09 BR BR9813860-0A patent/BR9813860A/pt not_active Application Discontinuation
- 1998-10-09 IL IL13523598A patent/IL135235A0/xx not_active IP Right Cessation
- 1998-10-09 KR KR10-2000-7003305A patent/KR100515196B1/ko not_active Expired - Fee Related
- 1998-10-09 CA CA002304374A patent/CA2304374A1/en not_active Abandoned
- 1998-10-09 PT PT98952186T patent/PT1027053E/pt unknown
- 1998-10-09 CN CNB988100363A patent/CN1154492C/zh not_active Expired - Fee Related
2000
- 2000-04-07 NO NO20001828A patent/NO20001828L/no unknown

Also Published As

Publication number	Publication date
HK1026845A1 (en)	2000-12-29
CN1154492C (zh)	2004-06-23
AU9794398A (en)	1999-05-03
DE69824619D1 (de)	2004-07-22
CZ297440B6 (cs)	2006-12-13
KR100515196B1 (ko)	2005-09-16
ATE269098T1 (de)	2004-07-15
EP1027053B1 (en)	2004-06-16
NO20001828D0 (no)	2000-04-07
AU748495B2 (en)	2002-06-06
CA2304374A1 (en)	1999-04-22
PL339774A1 (en)	2001-01-02
NZ503493A (en)	2001-11-30
CZ20001274A3 (cs)	2001-12-12
WO1999018961A1 (en)	1999-04-22
SK4672000A3 (en)	2001-09-11
CN1275080A (zh)	2000-11-29
EP1027053A1 (en)	2000-08-16
PL191993B1 (pl)	2006-08-31
DK1027053T3 (da)	2004-09-06
IL135235A0 (en)	2001-05-20
ES2221714T3 (es)	2005-01-01
HUP0003904A1 (hu)	2001-08-28
HUP0003904A3 (en)	2006-06-28
SK285332B6 (sk)	2006-11-03
DE69824619T2 (de)	2005-06-23
NO20001828L (no)	2000-05-15
EP1027053A4 (en)	2002-05-22
JP2001519392A (ja)	2001-10-23
US6187745B1 (en)	2001-02-13
RU2191020C2 (ru)	2002-10-20
KR20010030749A (ko)	2001-04-16
PT1027053E (pt)	2004-09-30
BR9813860A (pt)	2001-03-20

Publication	Publication Date	Title
UA65587C2 (en)	2004-04-15	Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
CA2061270C (en)	1997-01-28	Method and composition for treating reperfusion injury
WO2005082349A1 (en)	2005-09-09	Composition for the treatment of obesity comprising fumagillol derivative
EA039629B1 (ru)	2022-02-18	Фармацевтическая комбинация, содержащая селективный агонист рецептора s1p1
RU2000111495A (ru)	2002-02-27	Способ предотвращения нефротоксичности, вызванной циклоспорином и такролимусом
EP0534907A1 (en)	1993-03-31	The use of furanone derivatives for the prevention or treatment of autoimmune diseases
EP0305181A2 (en)	1989-03-01	Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
CN113413378A (zh)	2021-09-21	一种包含绿原酸的药物组合物在制备治疗早期阿尔茨海默病的药物中的用途
JPH06172168A (ja)	1994-06-21	免疫抑制剤
JP2004536076A (ja)	2004-12-02	Ｐ−ｇｐインヒビターおよび抗癲癇薬を含んでなる組合せ剤
CN112915192B (zh)	2022-10-25	Kp-1在制备治疗慢性肝病的药物中的用途
US20120029048A1 (en)	2012-02-02	Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies
HK1026845B (en)	2004-12-10	Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus
MXPA00003194A (en)	2002-02-26	Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
US20260027094A1 (en)	2026-01-29	Use of pyridone derivative
CN102973546A (zh)	2013-03-20	乙酰化白藜芦醇在制备预防和/或治疗肺纤维化疾病药物中的应用
CN1919184A (zh)	2007-02-28	吗替麦考酚酯分散片及其制备方法
Sinusitis	1995	Lamotrigine vs. Carbamazepine in Newly Diagnosed Epilepsy
GB2700235A (en)	2025-12-10	Combination therapy for envenomation
Lankin et al.	2001	HMG-CoA inhibitors induced the LDL oxidation
CN121337794A (zh)	2026-01-16	补骨脂素在制备治疗骨骼肌萎缩的药物中的应用
JP2009500447A (ja)	2009-01-08	セラシアマルセセンス（Ｓｅｒｒａｔｉａｍａｒｃｅｓｃｅｎｃｅ）Ｂ−１２３１ＫＣＴＣ０３８６ＢＰで分離したプロディジオシン（ｐｒｏｄｉｇｉｏｓｉｎ）を有効成分として含む急性移植片対宿主病（ａｃｕｔｅｇｒａｆｔ−ｖｅｒｓｕｓ−ｈｏｓｔｄｉｓｅａｓｅ）の予防または治療用組成物
Lasocki et al.	2001	L-carnitine prevents myocyte ceramide accumulation and caspase-3 activation in doxorusicin-induced cardiomyopathy in rats
Lasocki et al.	2001	Doxorubicin cardiomyopathy in rats: Comparison of the intraperitoneal and intravenous administration routes
Lascano et al.	2001	Action potential shortening due to opening of ATP-dependent potassium channels attenuates post-ischemic stunning by reducing calcium influx in conscious sheep